Today, the Swedish Government announced that the BICO Group is one of three companies nominated for the Export Success of the Year 2021 award. In an effort by the government to promote Swedish exports, the award honors companies that have made particularly meritorious efforts in inspiration and development.
The award ceremony will take place at the Ministry for Foreign Affairs in Stockholm on October 22 and will be hosted by the Minister for Foreign Trade Anna Hallberg, as well as HRH Prince Daniel.
"We are very honored by this nomination, and I am confident that our success is largely due to the creation of a unique group that offers the world's most expansive portfolio of bio convergence products and solutions," said Erik Gatenholm, CEO and co-founder, BICO. "Our mission is to solve the health challenges we face by combining biology, engineering, robotics and technology. Our sales organization is extremely customer-focused, and our R&D department drives innovation together with our customers, as today's challenges requires complex and multifaceted solutions."
The Government's nomination for BICO reads:
"Bico Group (biotechnology in health care and medicine)
Bico Group is at the forefront of biotechnology's applications in health care (bio convergence) and has received considerable international attention for its success, especially in the field of 3D printing of tissues and organs.
In just five years, the company has grown from a startup to positioning itself in 65 markets worldwide. Most of Bico Group's production and supplier base is in Sweden and around 200 jobs have been created.
BICO Group works to support the UN Sustainable Development Goals. Among other projects, it promotes the recycling of used bio-printers (Responsible Return Program) and offers products to minimize the number of pipettes used in laboratories. In addition, Bico Group’s solutions contribute to reducing animal testing."
For further information, please contact:
Isabelle Ljunggren, Head of Communications
Phone (Sweden): +46 70 830 0890
This information was submitted for publication, through the agency of the contact persons set out above, on October 15, at 4 pm (CEST).
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.
With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
The Group’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com